Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (May 2017)
19 slides from Vivani Medical's investor presentation, May 25, 2017
Slide 1: A Better Way of Life for Patients
NASDAQ: EYES A Better Way of Life for Patients May 2017 NASDAQ: EYES
Slide 2: Forward Looking Statements
NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward - loo
Slide 3: Second Sight Medical Products: Our Mission
NASDAQ: EYES Second Sight Medical Products, Inc. Enabling blind individuals to achieve greater independence & quality of life with implantable visual prosthetics Our Mission
Slide 4: Restoring Vision With Neurostimulation
NASDAQ: EYES Restoring Vision With Neurostimulation Worlds First Bionic Eye • Neurostimulation platform to address multiple forms of blindness • Demonstrated clinical benefit out to nearly 10 years post implant • 375+ issued patents Currently Available • Regulatory clearance in U.S., EU E.U. & other
Slide 5: Video: Bionic Eye Gives Sight to the Blind
NASDAQ: EYES Video: Bionic Eye Gives Sight to the Blind 5 http://www.bloomberg.com/news/videos/2015 - 05 - 21/bionic - eyes - give - second - sight - to - the - blind
Slide 6: Large Targeted Patient Population: 8+ Million
NASDAQ: EYES Large Targeted Patient Population: 8+ Million • Age - Related Macular Degeneration (AMD) • Clinical trial in dry AMD underway in U.K. 2.0M • Other forms of untreatable blindness • Eye trauma, optic nerve disease & other causes • Feasibility study begins in ‘17 5.8M 6 0.4M End - Stage Re
Slide 7: Second Sight ARGUS II Technology
NASDAQ: EYES Second Sight ARGUS II Technology Using a camera housed in a patient’s glasses, images are collected and converted into a series of small electrical pulses. These pulses are transmitted wirelessly to an electrode array on the surface of the retina. These pulses stimulate the remaining ce
Slide 8: Second Sight Orion I Technology
NASDAQ: EYES Second Sight Orion I Technology Leverages ARGUS II technology. Camera housed in a patient’s glasses collects images and converts into a series of small electrical pulses These pulses are transmitted wirelessly to an electrode array on the surface of the brain, bypassing the eye and the
Slide 9: Established Technology Leadership
NASDAQ: EYES Established Technology Leadership 9 • Over 375 patents issued • Over 125 patents pending Pioneering Technology Groundbreaking Research Recognized Leadership • 75+ scientific publications • 6 clinical & post - approval studies • Demonstrated benefit out to ~10 years post - implant • Nume
Slide 10: Neurostimulation Emerges as First Effective Treatment for Blindness
NASDAQ: EYES Neurostimulation Emerges as First Effective Treatment for Blindness 10 Retinal Prosthesis Competitors CE Mark Widely Reimbursed in Europe FDA Approved Reimbursed in USA Second Sight, Argus®II ✔ ✔ ✔ ✔ Retina implant (Germany) ✔ ✗ ✗ ✗ Pixium Vision (France) ✔ ✗ ✗ ✗ Nidek Co., Ltd. (Japan)
Slide 11: Expanding Reimbursement Coverage
NASDAQ: EYES Expanding Reimbursement Coverage 11 • 5 of 12 MAC* jurisdictions (~40% of US population) with positive coverage decision • Attained new CPT codes for initial programming and reprogramming of Argus II • $150k reimbursement rate set for 2017 • Continue coverage expansion to remaining MAC
Slide 12: 2017 Key Strategic Objectives
NASDAQ: EYES 2017 Key Strategic Objectives Validate revised Centers of Excellence commercial model in U.S. in order to drive adoption Demonstrate the ability to treat better - sighted RP patients in order to expand our treatable population beyond end stage RP patients Implant Orion I in humans, crea
Slide 13: Strengthening Centers of Excellence
NASDAQ: EYES Strengthening Centers of Excellence Partner with leading medical institutions to establish a network of high - quality surgical centers that are capable of treating a higher volume of patients Goal • New rehab program that incorporates best practices • Utilize rehab specialists with cer
Slide 14: Treating Better-Sighted Patients with Argus II Enhancements
NASDAQ: EYES Treating Better - Sighted Patients with Argus II Enhancements 14 Clinical Testing of Current Argus II Technology in Better - Sighted RP Patients Clinical Testing of Argus II Enhancements in Better - Sighted RP & AMD Patients • New external components for streamlined appearance • Softwar
Slide 15: Expanding into Potential 5.8M Patient Market with Orion I
NASDAQ: EYES Expanding into Potential 5.8M Patient Market with Orion I Leverage existing Argus II technology Bypass the optic nerve and directly stimulate the visual cortex Animal implants explanted & histology complete First in human feasibility assessment complete (n=1) with positive outcomes Begi
Slide 16: Second Sight Select Financials
NASDAQ: EYES Second Sight Select Financials 16 *Non - GAAP adjusted net loss excludes non - cash expenses including stock - based compensation and reserve for excess inventory. (USD $ in Thousands) Q1 2017 Q1 2016 FY 2016 FY 2015 Implants 14 10 42 75 Revenue $1,009 $1,053 $3,985 $8,950 Gross Profit
Slide 17: A Better Way of Life for Patients
NASDAQ: EYES A Better Way of Life for Patients 17 Improved Orientation and Mobility Greater Independence Significant Improvement in Quality of Life Enhanced Connection to Loved Ones
Slide 18: Second Sight Investment Highlights
NASDAQ: EYES Second Sight Investment Highlights Technology Leadership • First and only treatment approved for sale in the US, EU, Saudi Arabia, Turkey and Canada • Robust IP portfolio with 500+ patents issued and pending • Significant first mover advantage with 5+ year lead over any other therapeuti
Slide 19: Contacts
NASDAQ: EYES Retail Investor Relations Greg Falesnik Managing Director MZ North America Direct: 949 - 385 - 6449 Greg.Falesnik@mzgroup.us Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818 - 833 - 5000 www.secondsight.com Institutional Investor Relations
Second Sight Medical Products — Investor Presentation (May 2017) on 6ix